Larry,
From the 10K of SNAP:
The Company's human receptor-targeted drug design technology is being
utilized or has been utilized in a number of different research and drug
discovery programs. Some of these programs are currently being conducted by the
Company independently. Others may have been conducted by the Company
independently or in collaboration with pharmaceutical companies but are
currently inactive and available for licensing by the Company. Finally, some of
the programs are being conducted by the Company in joint research programs with
its collaborative partners or by the Company's licensees.
Total operating expenses incurred by the Company for each of the fiscal
years 1999, 1998 and 1997 were $19,652,000, $19,576,000 and $17,853,000,
respectively, of which approximately $1,759,000, $7,182,000 and $9,785,000,
respectively, was funded by the Company's collaborative partners during such
years. In 1998, the Company increased its internal research and development
spending in part as a result of the expiration of its collaboration with
Novartis and the termination of the associated research funding provided by
Novartis. The Company again increased internal research and development spending
during 1999, in part as a result of the July 31, 1999 expiration of its
collaboration with Lilly and the termination of the associated research funding
provided by Lilly and the February 28, 1999 expiration of its collaboration with
Merck and the termination of the associated research funding provided by Merck.
They only have one partner left Grunenthal (sp) and they are not providing any funding. |
